Serological cross-reactivity using a SARS-CoV-2 ELISA test in acute Zika virus infection, Colombia

Abstract

Highlights Colombia as an endemic country for Dengue, Chikungunya, and Zika virus. Co-epidemics of SARS-CoV-2 with other etiologies is a matter for concern. Serological cross-reactivity in acute Zika infection using a SARS-CoV-2 ELISA test.

Development of a Fast SARS-CoV-2 IgG ELISA, Based on Receptor-Binding Domain, and Its Comparative Evaluation Using Temporally Segregated Samples From RT-PCR Positive Individuals

“…The sample corresponds to a febrile pediatric patient positive for dengue IgM antibodies. There are contradictory reports in the literature on the possible false positivity of positive dengue or Zika samples in the SARS-CoV-2 antibody assay (Faccini-Martínez et al, 2020;Lau et al, 2020a,b;Lustig et al, 2020). Based on in-silico analysis, one report suggests some similarities between the part of the HR2 domain of the SARS-CoV-2 spike protein and the flavivirus envelope (Lustig et al, 2020).…”

Detection of Anti-Nucleocapsid Antibody in COVID-19 Patients in Bangladesh Is not Correlated with Previous Dengue Infection

“…To the best of our knowledge, our study is the first report on antibody responses to the SARS CoV-2 N-protein in Bangladesh. In light of the previous reports on pre-pandemic flavivirus serum showing cross-reactivity with SARS-CoV-2 S protein [ 18 , 19 , 21 ] and the predictions of shared epitopes on S-protein RBD and dengue E protein [ 20 ], the question was asked whether the detection of N-protein specific IgA or IgG, unrelated to the neutralizing antibodies against the S-protein target, is affected by the anti-dengue IgG present in Bangladeshi patients suffering from COVID-19 disease and having previous dengue infection.…”

“…The emergence of pathogenic coronaviruses in flavivirus endemic populations has created an urgent need for SARS-CoV-2 serological tests, which discriminate between the anti-virus antibodies and accurately assess the seroprevalence of dengue fever and COVID-19 [ 16 , 17 ]. Cross-reactivity between SARS-CoV-2 spike (S) protein and dengue envelope protein is indicated in pre-COVID-19 pandemic serum from flavivirus infection; 20% of 19 confirmed Brazilian Zika infection [ 18 ] and 22% of 70 dengue IgG positive travelers from Israel and Italy [ 19 ] show positive IgM and/or IgG reactivity in SARS-CoV-2 S RBD rapid tests and/or semi-quantitative ELISA. Molecular docking and computational algorithms on SARS-CoV-2 S-protein X-ray crystal structure and anti-dengue envelope (E) monoclonal antibodies (MAbs) predict significant surface interactions between the anti-DENV E MAbs and the S-protein receptor binding domain (RBD), including amino acids K417, Y449, Y453, Q493, G495, Q498, T500 and Y505, which mediate direct contact with the angiotensin-converting enzyme-2 (ACE-2) receptor [ 20 ].…”

COVID-19 Antibody Detecting Rapid Diagnostic Tests Show High Cross-Reactivity When Challenged with Pre-Pandemic Malaria, Schistosomiasis and Dengue Samples

“…In low-and middle-income countries (LMICs), COVID-19 Ab RDTs have also been deployed for triage, diagnosis and contact tracing [10][11][12]. Specificity testing of COVID-19 Ab RDTs so far has focused on seasonal coronaviruses (NL63, HKU1, 229E, OC43), SARS-CoV, cytomegalovirus, Epstein-Barr virus, human hepatitis B virus, Mycoplasma pneumoniae and parvovirus infection in addition to interfering conditions (rheumatoid factor, autoimmune pathologies and hyperglobulinemia) [8,[13][14][15][16][17][18][19][20][21][22][23][24][25][26]. Tropical diseases such as malaria, dengue, schistosomiasis and human African trypanosomiasis are well-known for their cross-reactivity with HIV-1 antibody LFA RDTs and malaria antigen RDTs [27][28][29][30].…”